▮ More

Intraday Alerts

Summit Therapeutics (SMMT) Has Tumbled To A New Low After Study Failed

By RTTNews Staff Writer ✉ | Published: 6/27/2018 9:52 AM ET

Summit Therapeutics (SMMT) announced Wednesday morning that its Phase 2 study of ezutromid failed to meet its primary or secondary endpoints.

Summit Therapeutics gapped open sharply lower this morning and is now down 10.35 at $2.29 on strong volume. The stock has tumbled to a new low for the year.

For comments and feedback contact: editorial@rttnews.com

Business News

Invest in the Best Pharma Stocks by Subscribing to RTT Biotech Investor.

Biotech Stocks Facing FDA Decision In March 2022

Biotech Stocks Facing FDA Decision In February 2022

Biotech Stocks Facing FDA Decision In January 2022

Latest Updates on COVID-19

US Covid Daily Cases Cross 100K Mark For Fourth Consecutive Day

US Daily Covid Cases Cross 100K Mark For Seventh Day This Month

As Cases Soar, Govt. Increases No. Of Free At-home Rapid Covid Tests

LumiraDx's SARS-CoV-2 Ag Test Receives WHO Emergency Use Listing

Covid-19 Summit To Consider Crucial Next Steps In Global Response

COVID-19: Drugs in Development

Follow RTT

Editor's Pick
Most Read
Most Emailed

Richemont FY22 Profit Climbs, Lifts Dividend; Stock Down

Wild Alaskan Cooked And Smoked Salmon Recalled

Ford Recalls 39,000 Expedition And Lincoln Navigator; Asks Owners To Park Outside Due To Fire Risk

FSIS Warns Against Plumrose USA's RTE Ham Product

America New York Ri Wang Food Recalls RTE Pork Sausage Products

Apple Delays 'three Days A Week In Office' Plan; Urges Staff To Wear Masks

FDA Urges Increased Imports Of Infant Formula To Meet Shortage

Walmart Q1 Profit Declines, Misses Estimates

Summit Therapeutics (SMMT) Has Tumbled To A New Low After Study Failed

Richemont FY22 Profit Climbs, Lifts Dividend; Stock Down

Wild Alaskan Cooked And Smoked Salmon Recalled

Ford Recalls 39,000 Expedition And Lincoln Navigator; Asks Owners To Park Outside Due To Fire Risk

FSIS Warns Against Plumrose USA's RTE Ham Product

America New York Ri Wang Food Recalls RTE Pork Sausage Products

Apple Delays 'three Days A Week In Office' Plan; Urges Staff To Wear Masks

FDA Urges Increased Imports Of Infant Formula To Meet Shortage

Walmart Q1 Profit Declines, Misses Estimates

Elon Musk Likely To Cut Offer Price For Twitter: Report

Vodafone FY22 Pre-tax Profit Down, Issues FY23 Earnings View

Ryanair FY22 Loss Narrows, Sees Reasonable Profitability In FY23; Stock Dips

FSIS Warns Against Weis Markets' RTE General Tso Chicken Meals

Tesla Removed From S&P 500 ESG Index

Alnylam Pharma Says Canada Authorizes OXLUMO For Treatment Of Primary Hyperoxaluria Type 1

ENPC, Grey Rock In Business Combination To Form Granite Ridge Resources

KKR Announces All-cash Acquisition Of ContourGlobal By Bidco - Quick Facts

Tencent Holdings Limited Q1 Profit Declines

Sika Acquires Liquid Waterproofing Company UGL

European Commission Plans To Terminate Purchase Agreement For Valneva's COVID-19 Vaccine Candidate

Burberry Annual Earnings Rise, Cuts Final Dividend; Backs Medium-term View

Bristol Myers Squibb: Phase 3 CheckMate -901 Trial Fails To Meet Primary Endpoint

Teva To Bring First Biosimilar For Lucentis In The UK - Quick Facts

UAE Grants Emergency Use Authorization For Valneva's COVID-19 Vaccine

Emergent BioSolutions To Acquire TEMBEXA Rights From Chimerix For Up To $337.5 Mln + Royalties

Sika Acquires Liquid Waterproofing Company UGL

JX Luxventure Explores Sale Of Its Loss Making Menswear Business

Apple Accused Of Intimidating Staff At World Trade Centre Store

Tencent Holdings Limited Q1 Profit Declines

Twitter Files Preliminary Proxy Statement In Connection With Transaction With Musk

Burberry Annual Earnings Rise, Cuts Final Dividend; Backs Medium-term View

EasyJet Plc Posts Narrower Loss In H1; Total Revenue Up 524%

New York City REIT Urges Shareholders To Vote For Re-election Of Director Elizabeth Tuppeny

Hugo Boss COO Heiko Schäfer To Step Down On May 31

Rattler Midstream Rallies On News Of Acquisition By Diamondback Energy

HomeServe To Be Acquired By Hestia Bidco

AbbVie Submits NDA For ABBV-951 To FDA For Treatment Of Advanced Parkinson's Disease